Dingdang Health Strengthens Innovative Drug Portfolio through Collaboration with Eli Lilly

Recently, Dingdang Health, an instant health-to-home service provider, has reached a cooperation with Eli Lilly and Company. Following the Beijing area, Dingdang Health officially launched the Tirzepatide Injection (Mounjaro) in its pharmacies in Guangzhou and Shenzhen.

Dingdang Health stated that relying on Eli Lilly's excellent innovative drug products and professional health science popularization capabilities, as well as Dingdang Health's extensive multifunctional smart pharmacy network, end-to-end intelligent warehouse distribution system, professional doctor and pharmacist service team, and full life cycle health management system, both parties will jointly bring one-stop health solutions to overweight/obesity, diabetes and other populations, improving the accessibility of medication and health management level.

Data shows that Eli Lilly and Company is a global leading pharmaceutical enterprise, achieving significant accomplishments in multiple fields such as diabetes, obesity, Alzheimer's disease, immune disorders, and oncology. The approval and market launch of its innovative drug tirzepatide (Mounjaro) fully demonstrates the company’s remarkable strength in the endocrinology and metabolism field, drawing widespread attention from people with diabetes or those seeking weight loss.

In recent years, Dingdang Health has been committed to creating a direct access point for smart health services and an intelligent professional pharmaceutical and medical service provider. It has continuously strengthened its supply chain construction and improved its digital service level: establishing four major smart warehouses across China, enhancing instant cold chain delivery services in Beijing, Shanghai, Guangzhou, and Shenzhen, and building an integrated management model of "instant pharmaceutical retail + health education + digital services" to help patients access disease education, online consultation, and regular follow-up services, thereby enhancing their self-management capabilities.

Not only that, but to meet the diverse medication needs of patients, Dingdang Health has launched and continuously expanded the "Original Research Drug Supply Alliance." This collaboration with Eli Lilly will undoubtedly help improve the accessibility of original research drugs in the Chinese market, benefiting patients in China.